Returning guests Drs. Gillessen and Sweeney discuss the value of treatments for advanced prostate cancer.
The Uromigos: Prostate Cancer
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news on prostate cancer.
Advertisement
Dr. Elena Castro of Virgen de la Victoria University Hospital in Malaga, Spain joins Tom and Brian to discuss PSMAFore data.
Silke Gillessen joins the podcast to discuss the top areas of consensus and controversy from APCCC 2025.
Dr. Tyler Seibert provides updates from the 2025 APCC Diagnostics conference.
Dr. Tanya Dorff discussed results of the STOPCAP trial from ASCO GU 2025, along with new data from TALAPRO-2.
Dr. Neeraj Agarwal joins Tom and Brian for an in-depth look at important data from TALAPRO-2.
Dr. Silke Gillessen is joined by special guests to discuss the top highlights from 2024 in the prostate cancer field.
Chuck Ryan, MD, joins the podcast to discuss various aspects of AR inhibition in prostate cancer.
Brian and Tom are joined by Dr. Chris Sweeney and Rob Jones to discuss the merits of various ARPIs in prostate cancer.
Returning guests Bertrand Tombal and Silke Gillessen join the podcast to dive into data from the 2024 APCCC.
Special guest Bertrand Tombal of Manchester Cancer Research Centre focuses on the historic and current data of AR inhibition
Listen to the podcast format of the panel on radioligand data in prostate cancer from Uromigos Live 2024.
Listen to the podcast format of the panel on T cell directed therapy in prostate cancer from Uromigos Live 2024.
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC.
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024.
Dr. Nima Sharifi joins The Uromigos to discuss mechanisms of resistance to hormone therapy in prostate cancer.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon discuss recent ESMO guideline changes on GU cancers.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos.
Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup.
Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round.
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
Dr. Nick James joins the podcast to discuss the recent Lancet Commission paper on prostate cancer.
Dr. Silke Gillessen gives a summary of APCCC 2024, including surgery versus RT, genetic and somatic testing, and more.
Chris Sweeney is joined by fellow experts to discuss mHSPC side effects such as bone weakness, hot flashes, and gynecomastia.
Professor Thomas Suter and Dr. Chuck Ryan discuss cardiovascular risks associated with hormone therapy in prostate cancer.
Drs. Thomas Zilli and Pierre Blanchard debate the use of radiation therapy in prostate cancer and oligometastatic disease.
Brian and Tom speak with Drs. Piet Ost and Jason Efstathiou on the data for and against radiation therapy in prostate cancer.
Daniel Goldstein returns to the podcast to discuss dosing changes in drugs such as nivolumab and pembrolizumab.
FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials in the GU setting.
Dr. Tanya Dorff discusses her work on a phase 1 study investigating acapatamab for advanced prostate cancer.
Michael Lattanzi, MD, joins the podcast to discuss treatment plans and research in the community oncology setting.
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer.
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer.
Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature.
Thomas Zilli joins the podcast to talk about the controversies surrounding radiotherapy for prostate cancer.
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue at APCCC 2024.
Silke Gillessen gives an overview of APCCC 2024 taking place in Lugano, Switzerland, in April.
The Uromigos close out the year with Tanya Dorff, MD, as she discusses her favorite prostate cancer studies of 2023.
Dr. Rahul Aggarwal discusses his recent paper on a phase 1/2 study on Lu-177 with pembrolizumab for mCRPC.
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC.
Dr. Nick James discusses the optimal patients to undergo radiotherapy for localized prostate cancer.
Dr. Michalski discusses brachytherapy techniques in prostate cancer, plus his work on a recent JCO article on the topic.
Jim Catto, PhD, FRCS, joins The Uromigos to discuss the 17-year follow-up data from the PROTECT prostate cancer study.
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
Chana Weinstock, MD joins the podcast to give career advice and answer our questions about the FDA.
We're joined by Walter M. Stadler, MD, to discuss how academic papers are accepted and the steps to take when submitting one.
Neeraj Agarwal, MD, joins us to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers.
Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT.
Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC.
Professor Nick James discusses the success of the STAMPEDE trial on the use of abiraterone in patients with prostate cancer.
An ODAC meeting determined that olaparib plus abiraterone for mCRPC should be restricted to patients with BRCA mutations.
Amar Kishan, MD, discusses his recent meta-analysis on the effects of concurrent neoadjuvant versus adjuvant sequencing.
The latest topics in urologic oncology are discussed at the 14th International Uro-Oncology Conference in Brazil.
Ursula Vogl, MD, discusses her research and career progression in the prostate and renal cell cancer fields.
Karine Tawagi, MD, from the University of Illinois, discusses her work in immune-related toxicities.
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC.
Michael Morris, MD discusses PARP inhibition for castration-resistant prostate cancer and the differing opinions on its use.
The Uromigos discuss the cost of quality adjusted life years with Daniel Goldstein, MD, from Davidoff Cancer Center.
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
Chris Sweeney, MBBS, joins The Uromigos to discuss 2022 research as well as further studies to be carried out in 2023.
Drs. Silke Gillessen and Dan George debate the use of olaparib and abiraterone in selected or unselected patients with mCRPC.
The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC.
Rob Jones discusses the current state of PARP inhibition in prostate cancer as well as differing opinions on the treatment.
Silke Gillessen and Nick James discuss a randomized trial on duration of adjuvant/salvage androgen ablation with XRT.
Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic.
Declan Murphy and Matt Cooperberg debate the use of interventions in active surveillance for patients with prostate cancer.
Dr. Oliver Sartor, medical director of Tulane Cancer Center, discusses his career development and work in prostate cancer.
Neal Shore describes his recent controversial paper and the over-treatment of patients with low-grade disease.
Phillip Kuo discusses phase 3 of the VISION trial that utilizes Lutetium-177 for the treatment of prostate cancer.
Drs. Rana McKay and Kim Chi question whether doublet or triplet therapy is appropriate in the first-line.
Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer.
Dr. Stefano Fanti focuses on PSMA therapy PET CT, particularly when to use this as a diagnostic.
Dr. Fred Saad describes the results of the PROpel Phase III trial.
Kim Chi, MD, describes the results of the MAGNITUDE trial,
Results from the ARASENS trial appear to have confirmed triple therapy as the new standard of care for mHSPC.
Pete Nelson, MD, describes mechanism of action and current clinical application in prostate cancer.
Silke Gillessen and Chris Sweeney join Tom and Brian to give a year in review.
Dr. Tanya Dorff discusses the TALAPRO-1 study and the role of PARP inhibitors in prostate cancer.
Dr. Karim Fizazi summarizes PEACE-1 data and describes the OS benefit of the triplet.
Dr. Gert Attard describes the practice-changing plenary data from the STAMPEDE study, presented at ESMO 2021.
Dr. Neeraj Agarwal describes the COSMIC-21 study on cabozantinib and atezolizumab in prostate cancer patients.
Dr. Larry Einhorn discusses advances in testis cancer treatments, including his experience in experimental therapeutics.
Dr. Phil Kantoff discusses his career progression, highlights from his research, and prostate cancer.
Dr. Neha Vapiwala discusses investigations and treatment for these patients.
Dr. Alberto Bossi discusses the role of adjuvant and salvage radiotherapy in advanced prostate cancer.
Ros Eeles gives a clinically focused overview of this topic.
Martin Eklund discusses his papers published in the New England Journal of Medicine and Lancet Oncology.
Dr. Maha Hussain discusses her career in genitourinary cancer with a focus on prostate cancer.
Peter Albers talks about exciting updates in prostate cancer research and picks his three highlights from EAU21.
Eric Small is quizzed about triplet therapy for first-line metastatic prostate cancer.
Silke Gillessen gives a safety update from this EORTC study focusing on fractures.
Chris Sweeney and Silke Gillessen give their opinion of recent data on radionuclides therapy in prostate cancer.
Dr. Kosj Yamoah of Moffitt Cancer Center describes the work he presented at ASCO 2021.
The Uromigos discuss an intriguing abstract that explores triplet therapy in metastatic hormone-sensitive prostate cancer.
Mike Morris explains how radionucleotides and PSMA-based therapeutics impact metastatic castration-resistant prostate cancer.
Chris Sweeney explores the prostate cancer program discussed at the ASCO GU Symposium 2021.
Dr. Neal Shore presents the impressive updates for the results of the Aramis trial.
Dr. Chuck Ryan delivers a review of the year in prostate cancer research and advancements.
Dr. James Eastham describes this study, which gives insight into perioperative treatments for high-risk prostate cancer.
Dr. Nick James gives us a quick summary of the STAMPEDE study and gives an overview of the latest data.
Dr. Cora Sternber discusses AMG 160 and the future of immunotherapy in CRPC.
Chris Sweeney discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC, a positive R3 trial in the ESMO plenary session.
In the final podcast of the Uromigos Virtual World Tour, Chris Sweeney discusses biomarkers in prostate cancer.
Dr. Ian Davis discusses why ANZUP has been so successful and the EnzaMet study.
The Uromigos World Tour lands in sunny Brazil with a discussion about research and prostate cancer with Dr. Fernando Maluf.
Thomas Hope is quizzed on the results of his study presented at ASCO 2020.
Mike Morris presents the findings in his prospective study.
Chris Sweeney explains why the trial was negative and answers questions.
Silke Gillessen and Chris Sweeney discuss how data from ESMO and GU ASCO meetings changed the way they treat prostate cancer.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.